Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1
članak: 3 od 158  
Back povratak na rezultate
Vojnosanitetski pregled
2020, vol. 77, br. 8, str. 804-810
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 13/09/2020
doi: 10.2298/VSP180519135B
Creative Commons License 4.0
Nivo endogenog testosterona i njegova korelacija sa lipidnim profilom kod muškaraca sa akutnim infarktom miokarda, starijih od 40 godina
aUniverzitet u Beogradu, Medicinski fakultet, Institut za reumatologiju
bKlinički centar Srbije, Centar za medicinsku biohemiju, Beograd
cKlinički centar Srbije, Klinika za kardiologiju, Beograd + Univerzitet u Beogradu, Medicinski fakultet
dUniverzitet u Beogradu, Medicinski fakultet + Klinički centar Srbije, Klinika za endokrinologiju dijabetes i bolesti metabolizma, Beograd

e-adresa: baracbranko3@gmail.com

Sažetak

Uvod/Cilj. Uticaj lipidnog profila na akutni infarkt miokarda (AIM) dobro je poznat. Nasuprot tome, uloga nivoa endogenog testosterona (T), kao jednog od mogućih prediktivnih faktora AIM i njegovo dejstvo na lipidni profil kod muškaraca sa AIM i dalje su kontroverzni. Cilj studije je bio da se odredi nivo endogenog T u AIM, kao i 6 meseci nakon AIM kod iste grupe ispitanika i da se uporedi sa nivoima T kod zdravih ispitanika. Pored toga, određena je i korelacija nivoa T sa parametrima lipidnog profila u AIM kao i šest meseci nakon AIM. Metode. Sprovedena je prospektivna studija u koju su bili uključeni muškarci podeljeni u tri grupe: grupu I činilo je 35 muškaraca, starosne dobi 55 ± 3 godine sa AIM; grupu II sačinjavalo je istih 35 muškaraca koji su analizirani 6 meseci nakon AIM, dok se grupa III sastojala od 20 zdravih ispitanika starosne dobi 57 ± 2,12 godina. Uzorci krvi kod ispitanika grupe I uzimani su u periodu od 12h od nastanka AIM. Kod istih ispitanika krv za analize uzeta je šest mesci nakon preležanog AIM (grupa II). U krvi su određivani nivoi: ukupnog holesterola, triglicerida, lipoproteina male gustine (LDL) holesterola, lipoproteina velike gustine (HDL) holesterola, apolioporoteina A1 (Apo A1), apolipoproteina B (Apo B), lipoproteina(a) [Lp(a)] i nivo endogenog T. Rezultati. Nivo T kod ispitanika sa AIM (grupa I) (16,86 ± 7,18 nmol/L), kao i kod istih ispitanika šest meseci nakon AIM (grupa II) (18,12 ± 7,96 nmol/L) bio je statistički značajno niži u odnosu na zdravu kontrolnu grupu iste starosti (27,11 ± 10,48 nmol/L) (p < 0,001). U grupi I dobijena je statistčki značajna, pozitivna korelacija između nivoa T i HDL holesterola (r = 0.403, p < 0,05) i visoko statistički značajna, pozitivna korelacija između nivoa T i Apo A1(r = 0,747, p < 0,01). U grupi II, takođe je nađena statistički značajna pozitivna korelacija između nivoa T i HDL holeserola (r = 0,388, p < 0,05), kao i nivoa T i Apo A1 (r = 0,354, p < 0,05). Zaključak. Ova studija je pokazala da su nivoi T kod mušaraca starijih od 40 godina sa AIM visoko stistički značajno niži u odnosu na nivoe T kod zdravih muškaraca iste životne dobi. Nivoi T kod ispitanika sa AIM zadržavaju statistički značajno niže vrednosti i šest meseci nakon AIM u poređenju sa zdravom kontrolnom grupom.

Ključne reči

Reference

Agledahl, I., Skjærpe, P., Hansen, J.B., Svartberg, J. (2008) Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: The Tromsø study. Nutrition, Metabolism and Cardiovascular Diseases, 18(4): 256-262
Cheetham, C.T., An, J., Jacobsen, S.J., Niu, F., Sidney, S., Quesenberry, C.P., Vandeneeden, S.K. (2017) Association of Testosterone Replacement with Cardiovascular Outcomes Among Men with Androgen Deficiency. JAMA Internal Medicine, 177(4): 491-9
Christou, G.A., Christou, K.A., Nikas, D.N., Goudevenos, J.A. (2016) Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. European Journal of Preventive Cardiology, 23(16): 1785-1796
Dickerman, R.D., Mcconathy, W.J., Zachariah, N.Y. (1997) Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. Journal of Cardiovascular Risk, 4(5): 363-366
Duell, P.B., Bierman, E.L. (1990) The Relationship Between Sex Hormones and High-Density Lipoprotein Cholesterol Levels in Healthy Adult Men. Archives of Internal Medicine, 150(11): 2317-20
Fortunati, N. (1999) Sex Hormone-Binding Globulin: Not only a transport protein: What news is around the corner?. Journal of Endocrinological Investigation, 22(3): 223-234
Godsland, I.F. (2002) Cnages in metabolic inflammatory and endothelial indices of carsiovascularrisk. u: Lunenfeld B., Gooren L. [ur.] Textbook of Men's Health, New York: Partenon Publishing Group, 317-325
Godsland, I.F., Wynn, V., Crook, D., Miller, N.E. (1987) Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questions. American Heart Journal, 114(6): 1467-1503
Haffner, S.M. (1996) Androgens in relation to cardiovascular disease and insulin resistend in aging male. u: Oddens B.J., Vermeulen A. [ur.] Androgens and the aging male, New York: Parthenon Publishing Group, p. 68-72
Haffner, S.M., Mykkänen, L., Valdez, R.A., Katz, M.S. (1993) Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. Journal of Clinical Endocrinology & Metabolism, 77(6): 1610-1615
Hämäläinen, E., Adlercreutz, H., Ehnholm, C., Puska, P. (1986) Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism, 35(6): 535-541
Layton, B.J., Li, D., Meier, C.R., Sharpless, J.L., Stürmer, T., Brookhart, A.M. (2018) Injection testosterone and adverse cardiovascular events: A case-crossover analysis. Clinical Endocrinology, 88(5): 719-727
Li, H., Mitchell, L., Zhang, X., Heiselman, D., Motsko, S. (2017) Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study. Journal of Sexual Medicine, 14(11): 1307-1317
Liting, P., Guoping, L., Zhenyue, C. (2015) Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol: Predictive value for CHD severity and prognostic utility in CHD patients. Herz, 40 Suppl 1: 1-7
Livingstone, C., Collison, M. (2002) Sex steroids and insulin resistance. Clinical Science, 102(2): 151-66
Loscalzo, J., Weinfeld, M., Fless, G.M., Scanu, A.M. (1990) Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis: An Official Journal of the American Heart Association, Inc, 10(2): 240-245
Meisinger, C., Loewel, H., Mraz, W., Koenig, W. (2005) Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: Results from the MONICA/KORA Augsburg cohort study. European Heart Journal, 26(3): 271-278
Muller, M., van der Schouw, Y.T., Thijssen, J.H.H., Grobbee, D.E. (2003) Endogenous Sex Hormones and Cardiovascular Disease in Men. Journal of Clinical Endocrinology & Metabolism, 88(11): 5076-5086
Oh, J.Y., Barrett-Connor, E., Wedick, N.M., Wingard, D.L. (2002) Endogenous Sex Hormones and the Development of Type 2 Diabetes in Older Men and Women: The Rancho Bernardo Study. Diabetes Care, 25(1): 55-60
Page, S.T., Mohr, B.A., Link, C.L., O'donnell, A.B., Bremner, W.J., Mckinlay, J.B. (2008) Higher testosterone levels are associated with increased high-density lipoprotein cholesterol in men with cardiovascular disease: Results from the Massachusetts Male Aging Study. Asian Journal of Andrology, 10(2): 193-200
Palabrica, T.M., Liu, A.C., Aronovitz, M.J., Furie, B., Lawn, R.M., Furie, B.C. (1995) Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine, 1(3): 256-259
Seidell, J.C., Björntorp, P., Sjöström, L., Kvist, H., Sannerstedt, R. (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism, 39(9): 897-901
Tikkanen, M.J., Nikkilä, E.A., Kuusi, T., Sipinen, S.U. (1982) High Density Lipoprotein-2 and Hepatic Lipase: Reciprocal Changes Produced by Estrogen and Norgestrel. Journal of Clinical Endocrinology & Metabolism, 54(6): 1113-1117
von Eckardstein, A., Schulte, H., Cullen, P., Assmann, G. (2001) Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol, 37(2): 434-9
von Eckardstein, A. (1998) Androgens, cardiovascular risk factors, and atherosclerosis. u: Nieschlag E., Behre H.M. [ur.] Testosterone: Action, Deficiency, Substitution, Berlin-Heidelberg: Springer, 2nd ed. pp. 229-58
Walldius, G., Jungner, I. (2004) Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine, 255(2): 188-205
Walldius, G., Jungner, I., Aastveit, A.H., Holme, I., Furberg, C.D., Sniderman, A.D. (2004) The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine (CCLM), 42(12): 1355-63
Walldius, G., Jungner, I. (2005) Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. European Heart Journal, 26(3): 210-212
Walldius, G., Jungner, I., Holme, I., Aastveit, A.H., Kolar, W., Steiner, E. (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet, 358(9298): 2026-2033
Wallenfeldt, K., Bokemark, L., Wikstrand, J., Hulthe, J., Fagerberg, B. (2004) Apolipoprotein B/Apolipoprotein A-I in Relation to the Metabolic Syndrome and Change in Carotid Artery Intima-Media Thickness During 3 Years in Middle-Aged Men. Stroke, 35(10): 2248-2252
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., Mcqueen, M., Budaj, A., Pais, P., Varigos, J., Lisheng, L. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 364(9438): 937-952
Zioncheck, T.F., Powell, L.M., Rice, G.C., Eaton, D.L., Lawn, R.M. (1991) Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. Journal of Clinical Investigation, 87(3): 767-771
Zmuda, J.M., Cauley, J.A., Kriska, A., Glynn, N.W., Gutai, J.P., Kuller, L.H. (1997) Longitudinal Relation between Endogenous Testosterone and Cardiovascular Disease Risk Factors in Middle-aged Men: A 13-Year Follow-up of Former Multiple Risk Factor Intervention Trial Participants. American Journal of Epidemiology, 146(8): 609-617